Categories: biotech company

  • Biotech founded by ex-Novo reseacher raises capital for new oral obesity treatment

    The biotech company, Pila Pharma, is raising 20 million Swedish kronor in an almost fully covered capital raise, which includes a stock option for future use. The goal is to expand the clinical pipeline with a separate dedicated obesity track and thereby explore more applications for the company's oral TRPV1 inhibitor for obesity and type 2 diabetes, a potential first-in-class candidate.

    Biotech founded by ex-Novo reseacher raises capital for new oral obesity treatment. Photo: Pila Pharma.

  • Hunt for Next Obesity Breakthrough Sends Biotech Stock Soaring

    Investors worldwide are scouring for their next big win after the door to the extremely lucrative obesity market was opened by pharmaceutical giants Novo Nordisk and Eli Lilly. Now benefiting on the Swedish stock exchange is a smaller Nordic biotech company.

Enter your email address to follow Epicent Public Relations A/S

When you choose to create a user account and follow a newsroom your personal data will be used by us and the owner of the newsroom, for you to receive news and updates according to your subscription settings.

To learn more about this, please read our Privacy Policy, which applies to our use of your personal data, and our Privacy Policy for Contacts, which applies to the use of your personal data by the owner of the newsroom you follow.

Please note that our Terms of Use apply to all use of our services.

You can withdraw your consent at any time by unsubscribing or deleting your account.
Check your inbox

Email sent to __email__. Click the link there to follow Epicent Public Relations A/S.

Okay